SIBNY SI-BONE, Inc. (ADR) Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
13:00
Feb 04 ◎
Mike Mahoney Chairman and Chief Executive Officer, Boston Scientific Cor… BSX Q4 FY25 call
Intracept procedure received expanded reimbursement coverage, and BSX is launching the Intracept Edge Stylet to improve the treatment experience. — Expanded coverage and new tooling may accelerate adoption of basivertebral nerve ablation, potentially impacting competitors like SI-BONE.
SIBNY
MED

About SIBNY Analyst Coverage

Buzzberg tracks SIBNY (SI-BONE, Inc. (ADR)) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Mike Mahoney.